Psychological and quality of life changes in patients using GLP-1 analogues

Grant, Paul; Lipscomb, David; Quin, John

doi:10.1016/j.jdiacomp.2011.03.002

Cited by 50 publications

(38 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also a GLP-1 analogue therapy, i.e. exenatide has been discussed to exert antidepressant properties [157]. As compared with new insulin, treatment satisfaction, well-being score and the Hospital Anxiety and Depression Scale scores were significantly reduced in exenatide as compared with insulin-treated patients.…”

Section: Experimental Medications Focusing Primarily On Metabolic Aspmentioning

confidence: 99%

“…As compared with new insulin, treatment satisfaction, well-being score and the Hospital Anxiety and Depression Scale scores were significantly reduced in exenatide as compared with insulin-treated patients. Although exenatide and insulin appear to have similar efficacy for the treatment of type 2 diabetes mellitus, exenatide affects both physiological and psychological parameters and might be used as an adjunctive therapy for depression in the context of diabetes [157]. In addition, the use of gram-negative antibiotics has been discussed to offer a potential therapeutic approach for the adjuvant treatment of depression [158].…”

Section: Experimental Medications Focusing Primarily On Metabolic Aspmentioning

confidence: 99%

See 1 more Smart Citation

Nutritional Aspects of Depression

Lang

Beglinger

Schweinfurth

et al. 2015

Cell Physiol Biochem

203

127

View full text Add to dashboard Cite

Several nutrition, food and dietary compounds have been suggested to be involved in the onset and maintenance of depressive disorders and in the severity of depressive symptoms. Nutritional compounds might modulate depression associated biomarkers and parallel the development of depression, obesity and diabetes. In this context, recent studies revealed new mediators of both energy homeostasis and mood changes (i.e. IGF-1, NPY, BDNF, ghrelin, leptin, CCK, GLP-1, AGE, glucose metabolism and microbiota) acting in gut brain circuits. In this context several healthy foods such as olive oil, fish, fruits, vegetables, nuts, legumes, poultry, dairy and unprocessed meat have been inversely associated with depression risk and even have been postulated to improve depressive symptoms. In contrast, unhealthy western dietary patterns including the consumption of sweetened beverage, refined food, fried food, processed meat, refined grain, and high fat diary, biscuits, snacking and pastries have been shown to be associated with an increased risk of depression in longitudinal studies. However, it is always difficult to conclude a real prospective causal relationship from these mostly retrospective studies as depressed individuals might also change their eating habits secondarily to their depression. Additionally specific selected nutritional compounds, e.g. calcium, chromium, folate, PUFAs, vitamin D, B12, zinc, magnesium and D-serine have been postulated to be used as ad-on strategies in antidepressant treatment. In this context, dietary and lifestyle interventions may be a desirable, effective, pragmatical and non-stigmatizing prevention and treatment strategy for depression. At last, several medications (pioglitazone, metformin, exenatide, atorvastatin, gram-negative antibiotics), which have traditionally been used to treat metabolic disorders showed a certain potential to treat depression in first randomized controlled clinical trials.

show abstract

Section: Experimental Medications Focusing Primarily On Metabolic Aspmentioning

confidence: 99%

Section: Experimental Medications Focusing Primarily On Metabolic Aspmentioning

confidence: 99%

Nutritional Aspects of Depression

Lang

Beglinger

Schweinfurth

et al. 2015

Cell Physiol Biochem

203

127

View full text Add to dashboard Cite

show abstract

“…Additionally, 2.4% of liraglutide 3 mg injection recipients had insomnia and 2.0% had anxiety, compared with 1.7% and 1.6 %, respectively, of placebo recipients. Of note, GLP-1 analogues have been reported to produce enhanced wellbeing in patients with diabetes [102].…”

Section: Liraglutide 3mg Injectionmentioning

confidence: 99%

Managing comorbid obesity and depression through clinical pharmacotherapies

McElroy

Guerdjikova

Mori

et al. 2016

Expert Opinion on Pharmacotherapy

View full text Add to dashboard Cite

When treating a patient with a mood disorder and obesity, both conditions need to be a focus of clinical attention. Psychotropic medications that have minimal weight gain effects should be used if possible. Weight-loss agents can probably be used in some mood disorder patients, but must be done so cautiously and with a full understanding of their potential psychiatric effects and interactions with psychotropic medications. Knowledge of the pharmacotherapy of binge eating and psychotropic-induced weight gain is also crucial.

show abstract

“…Several studies have shown how GLP-1 can have central effects other than those relating to blood glucose, such as appetite suppression and improvements in mood and quality of life factors. 10 GLP-1 action in the hypothalamic accurate nucleus improves glucose tolerance through centrally-acting mechanisms similar to leptin and FGF-19.…”

Section: Thinking About Diabetesmentioning

confidence: 99%